Évelyn Traina

Dr. Évelyn Traina

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2024 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
Geraldo DuarteGeraldo Duarte
Geraldo Duarte
ILIara Moreno Linhares
Iara Moreno Linhares
RKRegis Kreitchmann
Regis Kreitchmann
ATAndrea da Rocha Tristão
Andrea da Rocha Tristão
ÉTÉvelyn Traina
Évelyn Traina
JAJoelma Queiroz Andrade
Joelma Queiroz Andrade
Key points • The balanced vaginal microbiome is the main factor defending the vaginal environment against infections. Lactobacilli play a key role in this regard, maintaining the vaginal pH within the normal range (3.8 to 4.5). •Hormonal and immune adaptations resulting from pregnancy influence changes in the vaginal microbiome during pregnancy. •An altered vaginal microbiome […] Key points • The balanced vaginal microbiome is the main factor defending the vaginal environment against infections. Lactobacilli play a key role in this regard, maintaining the vaginal pH within the normal range (3.8 to 4.5). •Hormonal and immune adaptations resulting from pregnancy influence changes in the vaginal microbiome during pregnancy. •An altered vaginal microbiome […]

21 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CLCarolina Longo
Carolina Longo
MSMauricio Saito
Mauricio Saito
PCPedro Castro
Pedro Castro
ÉTÉvelyn Traina
Évelyn Traina
HWHeron Werner
Heron Werner
Edward Araujo JúniorEdward Araujo Júnior
Edward Araujo Júnior
Coxsackievirus group B (CVB), a member of the Picornaviridae family and enterovirus genus, poses risks during pregnancy due to its potential to cause severe fetal and neonatal infections. Transmission primarily occurs through fecal–oral routes, with infections peaking mostly in warmer months. Vertical transmission to the fetus can lead to conditions such as myocarditis, encephalitis, and systemic neonatal disease, presenting clinically as severe myocardial syndromes and neurological deficits. Diagnostic challenges include detecting asymptomatic maternal infections and conducting in utero assessments using advanced techniques like RT-PCR from amniotic fluid samples. Morbidity and mortality associated with congenital CVB infections are notable, linked to preterm delivery, fetal growth restriction, and potential long-term health impacts such as type 1 diabetes mellitus and structural cardiac anomalies. Current treatments are limited to supportive care, with emerging therapies showing promise but requiring further study for efficacy in utero. Preventive measures focus on infection control and hygiene to mitigate transmission risks, which are crucial especially during pregnancy. Future research should aim to fill knowledge gaps in epidemiology, improve diagnostic capabilities, and develop targeted interventions to enhance maternal and fetal outcomes.

17 December 2025 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Open access
ABAntonio Braga
Antonio Braga
Geraldo DuarteGeraldo Duarte
Geraldo Duarte
RKRegis Kreitchmann
Regis Kreitchmann
GCGustavo Yano Callado
Gustavo Yano Callado
JHJoh Hama
Joh Hama
Edward Araujo JúniorEdward Araujo Júnior
Edward Araujo Júnior
To synthesize current evidence on Oropouche virus infection during pregnancy, with particular emphasis on transmission dynamics, clinical presentation, diagnostic challenges, and emerging data on vertical transmission and adverse fetal and perinatal outcomes. A narrative review of the literature was conducted to summarize available data on Oropouche virus infection in pregnancy. Searches were performed in PubMed/MEDLINE, Scopus, Web of Science, Embase, SciELO, and LILACS, complemented by official reports from the World Health Organization (WHO), Pan American Health Organization (PAHO), Centers for Disease Control and Prevention (CDC), and the Brazilian Ministry of Health. The search strategy included combinations of the following keywords: "Oropouche virus", "Oropouche fever", "pregnancy", "vertical transmission", "congenital infection", "fetal outcomes", "arbovirus", and "perinatal outcomes". Original studies, case reports, case series, reviews, surveillance reports, and clinical guidelines published in English, Portuguese, or Spanish were considered. No formal quality assessment or meta-analysis was performed, consistent with a narrative review design. Oropouche virus is an emerging arboviral infection in Latin America, with a rapidly increasing number of cases reported in Brazil and neighboring countries. Transmission occurs mainly via Culicoides paraensis midges and Culex mosquitoes. Although infection is usually self-limiting, clinical manifestations frequently overlap with other arboviral diseases, complicating diagnosis. Growing evidence indicates that vertical transmission can occur, with confirmed cases associated with fetal demise and congenital anomalies, including microcephaly, ventriculomegaly, corpus callosum dysgenesis, cerebral atrophy, posterior fossa abnormalities, and arthrogryposis. Viral neurotropism and detection of viral RNA in placental and fetal tissues support a plausible teratogenic potential. Diagnostic confirmation relies on RT-PCR during the acute phase and serological testing thereafter. In pregnancy, management requires referral to high-risk obstetric care, serial fetal imaging, particularly focused on central nervous system evaluation, and multidisciplinary perinatal planning. Oropouche virus infection should be recognized as an emerging threat to maternal and fetal health. Accumulating evidence of vertical transmission and congenital involvement underscores the need to include Oropouche virus in the differential diagnosis of febrile illness during pregnancy in endemic areas. In the absence of specific treatment or licensed vaccines, prevention relies on vector control and personal protective measures. Strengthened surveillance systems, standardized diagnostic protocols, and prospective studies are urgently needed to clarify the magnitude of fetal risk, mechanisms of vertical transmission, and long-term outcomes of congenitally exposed infants.

28 July 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
AEAna Clara Assis Alves Emerick
Ana Clara Assis Alves Emerick
Letícia Castilho YamanakaLetícia Castilho Yamanaka
Letícia Castilho Yamanaka
SPStefany Silva Pereira
Stefany Silva Pereira
TSTammy Caram Sabatine
Tammy Caram Sabatine
TCTaline de Brito Cavalcante
Taline de Brito Cavalcante
ÉTÉvelyn Traina
Évelyn Traina
Human T-cell lymphotropic virus (HTLV), a retrovirus associated with severe conditions such as leukemia/lymphoma and myelopathy, exhibits variable global prevalence, with higher rates observed in regions such as northeastern Brazil and sub-Saharan Africa. While intrauterine transmission can occur via viral expression in placental tissue and contact with umbilical cord blood, the predominant route is vertical transmission through breastfeeding. Diagnostic testing, particularly serological screening with ELISA and confirmatory methods such as Western blot and PCR, is essential for early detection during pregnancy. The implementation of prenatal screening programs, as seen in Japan and Brazil, has proven effective in reducing vertical transmission by guiding interventions such as breastfeeding cessation in infected mothers. Beyond clinical implications, the psychosocial impact on affected pregnant women highlights the need for an interdisciplinary approach. Although the association between HTLV infection and adverse obstetric outcomes remains controversial, studies suggest increased risks of preterm birth, low birth weight, and other neonatal complications. Given the importance of early diagnosis and prevention, universal prenatal screening protocols represent a critical strategy to reduce viral transmission and its long-term consequences.

25 June 2026 in Women
Verified
Journal Article
Open access
PDF file
AHAlan Roberto Hatanaka
Alan Roberto Hatanaka
ABAntonio Braga
Antonio Braga
ÉTÉvelyn Traina
Évelyn Traina
LTLarissa Keren Azevedo Teixeira
Larissa Keren Azevedo Teixeira
CLCarolina Longo
Carolina Longo
Edward Araujo JúniorEdward Araujo Júnior
Edward Araujo Júnior
Toxoplasmosis remains one of the most common parasitic infections affecting humans, with significant implications for pregnancy and fetal health. Maternal primary infection during gestation can result in transplacental transmission of Toxoplasma gondii, leading to a wide spectrum of congenital disease. The risk of vertical transmission increases with gestational age, whereas disease severity is inversely related—early infections causing severe neurological and ocular damage, and late infections often resulting in subclinical forms. Advances in serological testing, including IgG avidity assays and molecular diagnostics such as PCR on amniotic fluid, have improved early detection and management. Prenatal treatment with spiramycin or pyrimethamine–sulfadiazine–folinic acid combinations has been associated with reduced transmission and less severe fetal disease in several studies, although the magnitude of benefit remains debated. Long-term follow-up is essential, as late-onset manifestations, particularly chorioretinitis and neurodevelopmental impairment, are common. This narrative review was based on a comprehensive literature search of major medical databases and summarizes current knowledge on the epidemiology, pathophysiology, diagnosis, treatment, and outcomes of toxoplasmosis in pregnancy. Particular emphasis is placed on high-prevalence countries, where greater parasite genetic diversity, distinct epidemiological patterns, and a higher burden of congenital disease pose unique clinical and public health challenges. Despite progress in understanding parasite biology, pathogenesis, and treatment efficacy, congenital toxoplasmosis continues to be underdiagnosed and underreported, especially in low-resource settings. Ongoing challenges include optimizing screening strategies, ensuring access to standardized therapies, and strengthening surveillance systems.

10 November 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
LSLuisa Scomparim
Luisa Scomparim
GCGustavo Yano Callado
Gustavo Yano Callado
LMLivian Cássia De Melo
Livian Cássia De Melo
Marina RugnaMarina Rugna
Marina Rugna
SPStefany Silva Pereira
Stefany Silva Pereira
Edward Araujo JúniorEdward Araujo Júnior
Edward Araujo Júnior
Chikungunya virus (CHIKV) infection during pregnancy represents an increasing public health concern, especially in endemic and epidemic regions. The main concern is vertical transmission, particularly during the peripartum period, which can lead to severe neonatal outcomes such as encephalopathy, hematologic abnormalities, and long-term neurodevelopmental impairment. This review synthesizes current knowledge on pathophysiology, clinical manifestations, diagnosis, maternal and neonatal outcomes, and management of CHIKV infection in pregnancy. Diagnosis relies on clinical evaluation supported by laboratory confirmation, RT-PCR in the acute phase and IgM serology thereafter. Treatment is supportive, using acetaminophen as first-line therapy and corticosteroids for selected refractory cases. No antivirals or vaccines are approved for use in pregnancy as of 2025. Prevention is centered on vector control, personal protection, and epidemiological surveillance. Delivery planning and neonatal monitoring are essential when infection occurs close to term due to the high risk of peripartum transmission. Despite growing recognition of CHIKV’s maternal–fetal impact, significant gaps remain regarding long-term outcomes and optimal management strategies. Strengthening prenatal care, neonatal preparedness, and surveillance systems is crucial to mitigate adverse outcomes and inform future clinical and public health policies.